This page in English
Laddar profil information

Forskningsbeskrivning

Professor emerita i koagulationsforskning vid institutionen för molekylär medicin och kirurgi.

Margareta Blombäck studerade medicin vid Karolinska Institutet och hon disputerade 1958 inom koagulationsforskning. Hon blev 1969 chef för koagulationslaboratoriet vid Karolinska sjukhuset och 1986 professor i koagulationsforskning, emeritus sedan 1992. Hon har varit aktiv inom International Society of Trombosis and Hemostasis.

Margareta Blombäcks forskning handlar om blodkoagulering, dvs. blodets förmåga att levra sig. Tillsammans med sin make Birger Blombäck, kunde hon redan på 1950-talet rena fram fibrinogen samt Faktor VIII som saknas hos patienter med den vanligaste formen av klassisk blödarsjuka (hemofili A).

Margareta och Birger Blombäck kunde också identifiera det protein som saknas hos personer med den åländska blödarsjukan (von Willebrands sjukdom), en upptäckt som ledde till att patienter kunde få en bättre och tidigare behandling i jämförelse med resten av världen. Margareta Blombäck har tilldelats flera priser för sina betydande forskningsinsatser. 

Länkar

Publikationer

An increased tendency in fibrinogen activity and its association with a hypo-fibrinolytic state in early stages after injury in patients without acute traumatic coagulopathy (ATC)
He S, Blombäck M, Boström F, Wallen H, Svensson J, Östlund A
Journal of thrombosis and thrombolysis 2018;45(4):477-485

A ROTEM method using APTT reagent and tissue factor as the clotting activators may better define bleeding heterogeneity in moderate or severe haemophilia A (part I: Study in plasma samples)
He S, Eelde A, Petrini P, Wallen H, Gabrielsson L, Svensson J, et al
Thrombosis research 2018;171():7-13

Fifth Åland Island conference on von Willebrand disease
Berntorp E, Ågren A, Aledort L, Blombäck M, Cnossen Mh, Croteau Se, et al
Haemophilia : the official journal of the World Federation of Hemophilia 2018;24 Suppl 4():5-19

Global impairments in the haemostasis systems after cardiopulmonary bypass
He S, Blombäck M, Wallén H, Jeppsson A, Grass S
Thrombosis research 2017;151():63-66

Monitoring of coagulation factor therapy in patients with von Willebrand disease type 3 using a microchip flow chamber system
Ågren A, Holmström M, Schmidt De, Hosokawa K, Blombäck M, Hjemdahl P
Thrombosis and haemostasis 2017;117(1):75-85

Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease
Mörtberg J, Blombäck M, Wallén Å, He S, Jacobson Sh, Spaak J
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2016;27(4):401-7

Postoperative cerebral bleeding in a boy with suspected mild deficiency of fibrinogen and FXIII
Ranta S, Blombäck M, Magnusson M, He S
Thrombosis research 2016;141():66-8

Assays of fibrin network properties altered by VKAs in atrial fibrillation - importance of using an appropriate coagulation trigger
Ząbczyk M, Blombäck M, Majewski J, Karkowski G, Wallen Hn, Undas A, et al
Thrombosis and haemostasis 2015;113(4):851-61

Tranexamic acid--an old drug still going strong and making a revival
Tengborn L, Blombäck M, Berntorp E
Thrombosis research 2015;135(2):231-42

Fibrinogen depletion after plasma-dilution: impairment of proteolytic resistance and reversal via clotting factor concentrates
He S, Johnsson H, Zabczyk M, Hultenby K, Wallén H, Blombäck M
Thrombosis and haemostasis 2014;111(3):417-28

A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor
He S, Johnsson H, Zabczyk M, Hultenby K, Cao H, Blombäck M
British journal of haematology 2013;160(6):806-16

In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban
He S, Wallèn H, Bark N, Blombäck M
Journal of thrombosis and thrombolysis 2013;35(2):131-9

Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study
Svensson J, Bergman Ac, Adamson U, Blombäck M, Wallén H, Jörneskog G
Biochemical and biophysical research communications 2012;421(2):335-42

Agnes Henschen-Edman, MD, Ph.D. April 1, 1935 to October 23, 2011
Blomback M, Lord St
THROMBOSIS RESEARCH 2012;130(3):568-569

Impaired fibrinolytic capacity and increased fibrin formation associate with myocardial infarction
Leander K, Blombäck M, Wallén H, He S
Thrombosis and haemostasis 2012;107(6):1092-9

In vivo roles of factor XII
Renné T, Schmaier Ah, Nickel Kf, Blombäck M, Maas C
Blood 2012;120(22):4296-303

Memories of my research into von Willebrand's disease
Blomback M
HAEMOPHILIA 2012;18(1):3-6

von Willebrand disease biology
Blombäck M, Eikenboom J, Lane D, Denis C, Lillicrap D
Haemophilia : the official journal of the World Federation of Hemophilia 2012;18 Suppl 4():141-7

Changes in von Willebrand factor and ADAMTS13 during IVF
Westerlund E, Antovic A, Hovatta O, Eberg Kp, Blomback M, Wallen H, et al
BLOOD COAGULATION & FIBRINOLYSIS 2011;22(2):127-31

Decreased fibrin network permeability and impaired fibrinolysis in the acute and convalescent phase of ischemic stroke
Rooth E, Wallen Nh, Blomback M, He S
THROMBOSIS RESEARCH 2011;127(1):51-6

Effects on fibrin network porosity of anticoagulants with different modes of action and reversal by activated coagulation factor concentrate*
Blomback M, He S, Bark N, Wallen Hn, Elg M
BRITISH JOURNAL OF HAEMATOLOGY 2011;152(6):758-65

ETP - a sensitive marker of haemostasis in women undergoing in vitro fertilization
Westerlund E, Henriksson P, Wallen Nh, Hovatta O, Blomback M, Antovic A
THROMBOSIS RESEARCH 2011;:S129-S130

Inflammatory and haemostatic markers in idiopathic intracranial hypertension
Hannerz J, Antovic Jp, Blomback M, Edman G, Khademi M, Piehl F
JOURNAL OF INTERNAL MEDICINE 2011;270(5):496-9

Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome?
Skeppholm M, Kallner A, Malmqvist K, Blomback M, Wallen H
THROMBOSIS RESEARCH 2011;128(5):483-9

Molecular aspects in clinical hemostasis research at Karolinska Institutet
Blomback M
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 2010;396(1):131-4

The direct thrombin inhibitors (argatroban, bivalirudin and lepirudin) and the indirect Xa-inhibitor (danaparoid) increase fibrin network porosity and thus facilitate fibrinolysis
He S, Blomback M, Bark N, Johnsson H, Wallen Nh
THROMBOSIS AND HAEMOSTASIS 2010;103(5):1076-84

ADAMTS13 and von Willebrand factor concentrations in patients with diabetes mellitus
Skeppholm M, Kallner A, Kalani M, Jorneskog G, Blomback M, Wallen Hn
BLOOD COAGULATION & FIBRINOLYSIS 2009;20(8):619-26

Effects of Acetylsalicylic Acid on Increase of Fibrin Network Porosity and the Consequent Upregulation of Fibrinolysis
He S, Bark N, Wang H, Svensson J, Blomback M
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 2009;53(1):24-9

Haemostatic disturbances in women undergoing in vitro fertilization
Westerlund E, Wallen Nh, Hovatta O, Bjuresten K, Henriksson P, Blomback M, et al
THROMBOSIS RESEARCH 2009;:S135-S135

The plasma concentration of activated protein C appears normal in patients with haemophilia
Schulman S, Eelde A, Blomback M, Stenflo J
HAEMOPHILIA 2009;15(2):566-70

Can both EDTA and citrate plasma samples be used in measurements of fibrinogen and C-reactive protein concentrations?
Skeppholm M, Wallen Nh, Blomback M, Kallner A
CLINICAL CHEMISTRY AND LABORATORY MEDICINE 2008;46(8):1175-9

In Vitro Effects of Argatroban, Lepirudin, Bivalirudin, and Danaparoid on Fibrin Gel Permeability
He S, Wallen H, Johnsson H, Blomback M
SEMINARS IN THROMBOSIS AND HEMOSTASIS 2008;:91-96

Validation of a composite score for clinical severity of hemophilia
Schulman S, Eelde A, Holmstrom M, Stahlberg G, Odeberg J, Blomback M
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2008;6(7):1113-21

A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma
He S, Zhu K, Skeppholm M, Vedin J, Svensson J, Egberg N, et al
THROMBOSIS AND HAEMOSTASIS 2007;98(4):871-82

Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers
Majid K, Silveira A, Blomback M, Apelqvist J, Eliasson B, Eriksson Jw, et al
THROMBOSIS RESEARCH 2007;120(5):653-61

Coagulation abnormalities associated with severe isolated traumatic brain injury: Cerebral arterio-venous differences in coagulation and inflammatory markers
Nekludov M, Antovic J, Bredbacka S, Blomback M
JOURNAL OF NEUROTRAUMA 2007;24(1):174-80

Platelet activity, coagulation, and fibrinolysis during exercise in healthy males - Effects of thrombin inhibition by argatroban and enoxaparin
Li Nl, He S, Blomback M, Hjemdahl P
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2007;27(2):407-13

Platelet activity, coagulation, and fibrinolysis during exercise in healthy males: Effects of thrombin inhibition by argatroban and enoxaparin
Li Nl, He S, Blomback M, Hjemdahl P
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 2007;27(6):E51-E51

Platelet dysfunction in patients with severe traumatic brain injury
Nekludov M, Bellander Bm, Blomback M, Wallen Hn
JOURNAL OF NEUROTRAUMA 2007;24(11):1699-706

Preanalytical conditions that affect coagulation testing, including hormonal status and therapy
Isth Ssc Subcommittee Womens Hlth, Blomback M, Konkle Ba, Manco-johnson Mj, Bremme K, Hellgren M, et al
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2007;5(4):855-8

Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke
Rooth E, Wallen H, Antovic A, Von Arbin M, Kaponides G, Wahlgren N, et al
BLOOD COAGULATION & FIBRINOLYSIS 2007;18(4):365-70

Thrombosis and haemostasis research: Stimulating, hard work and fun
Blomback M
THROMBOSIS AND HAEMOSTASIS 2007;98(1):8-15

Obituary - Professor Shosuke Okamoto, 1917-2004
Blomback B, Blomback M
THROMBOSIS RESEARCH 2006;117(3):353-354

Hemostatic and inflammatory disturbances are present in patients with ischemic stroke
Rooth E, Wallon H, Antovic Jp, Blomback M, Von Arbin M, Kaponides G, et al
STROKE 2005;36(2):516-517

Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma
Antovic A, Blomback M, Sten-linder M, Petrini P, Holmstrom M, He S
BLOOD COAGULATION & FIBRINOLYSIS 2005;16(8):585-96

Marked increase of fibrin gel permeability with very low dose ASA treatment
Antovic A, Perneby C, Ekman Gj, Wallen Hn, Hjemdahl P, Blomback M, et al
THROMBOSIS RESEARCH 2005;116(6):509-17

Modifications of flow measurement to determine fibrin gel permeability and the preliminary use in research and clinical materials
He S, Cao H, Antovic A, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 2005;16(1):61-7

New overall haemostatic balance method in different conditions with haemostatic disturbances
Antovic A, He S, Blomback M
THROMBOSIS RESEARCH 2005;:109-110

Occurrence of cold activation of transfusion plasma during storage at+4 degrees C
Suontaka Am, Silveira A, Soderstrom T, Blomback M
VOX SANGUINIS 2005;88(3):172-80

Thrombin activatable fibrinolysis inhibitor antigen could not be detected in cerebrospinal fluid
Antovic Jp, Hannerz J, Nekludov M, Blomback M
THROMBOSIS AND HAEMOSTASIS 2005;93(1):178-9

Antithrombin antigen and activity in patients with acquired antithrombin deficiency - is there a difference?
Ungerstedt Js, Antovic J, Blomback M, Bremme K, Johnsson H
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2004;2(5):838-9

Does an enzyme other than thrombin contribute to unexpected changes in the levels of the different forms of thrombin activatable fibrinolysis inhibitor in patients with hemophilia A, hemophilia B and von Willebrand disease?
Antovic Jp, Schulman S, An Ssa, Greenfield Rs, Blomback M
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 2004;64(8):745-51

Overall hemostatic potential (OHP) assay - a possible tool for determination of prothrombotic pattern in FXII deficiency
Antovic Jp, Antovic A, Sten-linder M, Wramsby M, Blomback M
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2004;2(11):2058-60

Are results of fibrinogen measurements transferable?
Kallner A, Egberg N, Yu A, Merzoug-djilali R, Blomberg I, Jorneskog G, et al
CLINICAL CHEMISTRY AND LABORATORY MEDICINE 2003;41(6):804-8

Bedside monitoring of coagulation activation after challenging healthy volunteers with intravenous endotoxin
Ungerstedt Js, Soop A, Sollevi A, Blomback M
THROMBOSIS RESEARCH 2003;111(6):329-34

Changes in functional activities of plasma fibrinogen after treatment with methylene blue and red light
Suontaka Am, Blomback M, Chapman J
TRANSFUSION 2003;43(5):568-75

Clotting onset time may be a predictor of outcome in human brain injury: A pilot study
Ungerstedt Js, Grenander A, Bredbacka S, Blomback M
JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY 2003;15(1):13-8

Decreased levels of von Willebrand factor-cleaving protease in coronary heart disease and thrombotic thrombocytopenic purpura: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation
Yoo G, Blomback M, Schenck-gustafsson K, He S
BRITISH JOURNAL OF HAEMATOLOGY 2003;121(1):123-9

Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis in factor VIII deficient plasma and in hemophilia a patients?
Antovic Jp, Antovic A, Blomback M
BLOOD 2003;102(11):796A-797A

Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease - A prospective, randomized, double-blind, placebo-controlled study
Kalani M, Apelqvist J, Blomback M, Brismar K, Eliasson B, Eriksson Jw, et al
DIABETES CARE 2003;26(9):2575-80

Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance
Antovic A, Blomback M, Bremme K, Van Rooijen M, He S
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2003;1(12):2531-5

Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion
Jorneskog G, Hansson Lo, Wallen Nh, Yngen M, Blomback M
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2003;1(6):1195-201

Nicotinamide is a potent inhibitor of proinflammatory cytokines
Ungerstedt Js, Blomback M, Soderstrom T
CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2003;131(1):48-52

On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin
Edlund M, Blomback M, He S
BLOOD COAGULATION & FIBRINOLYSIS 2003;14(6):593-8

The role of recombinant factor VIIa(FVIIa) in fibrin structure in the absence of FVIII/FIX
He S, Blomback M, Ekman Gj, Hedner U
JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2003;1(6):1215-9

Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications
Antovic Jp, Yngen M, Ostenson Cg, Antovic A, Wallen Hn, Jorneskog G, et al
BLOOD COAGULATION & FIBRINOLYSIS 2003;14(6):551-6

Blood coagulation and fibrinolysis in acute ischaemic and haemorrhagic (intracerebral and subarachnoid haemorrhage) stroke: does decreased plasmin inhibitor indicate increased fibrinolysis in subarachnoid haemorrhage compared to other types of stroke?
Antovic J, Bakic M, Zivkovic M, Ilic A, Blomback M
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 2002;62(3):195-9

Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time
Edlund M, Blomback M, Fried G
BLOOD COAGULATION & FIBRINOLYSIS 2002;13(3):225-31

Discrepancy between antithrombin activity methods revealed in Antithrombin Stockholm: do factor Xa-based methods overestimate antithrombin activity in some patients?
Ungerstedt Js, Schulman S, Egberg N, Antovic J, Blomback M
BLOOD 2002;99(6):2271-2

Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?
Antovic Jp, Hamad Rr, Antovic A, Blomback M, Bremme K
THROMBOSIS AND HAEMOSTASIS 2002;88(4):644-7

Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women
Hall G, Blomback M, Landgren Bm, Bremme K
FERTILITY AND STERILITY 2002;78(6):1172-7

Elevated TAFIa/ai antigen levels are a marker for hyperfibrinolytic state in hemophilia patients.
Greenfield Rs, Antovic J, An Jy, Blomback M, An Ssa
BLOOD 2002;100(11):696A-697A

Measurement of blood and plasma coagulation time using free oscillating rheometry
Ungerstedt Js, Kallner A, Blomback M
SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION 2002;62(2):135-40

Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII
Antovic Jp, Antovic A, He S, Tengborn L, Blomback M
HAEMOPHILIA 2002;8(6):781-6

The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism
Antovic A, Blomback M, Bremme K, He S
BLOOD COAGULATION & FIBRINOLYSIS 2002;13(3):181-6

Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation
Antovic Jp, Blomback M
THROMBOSIS RESEARCH 2002;106(1):59-62

Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy
Bremme K, Van Rooijen M, Yu A, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 2001;12(2):149-55

Activation of the coagulation system occurs within rather than outside cutaneous haemangiomas
Antovic J, Bakic M, Milicevic R, Gojkovic G, Blomback M
ACTA PAEDIATRICA 2001;90(10):1137-40

Are increased levels of von Willebrand factor in chronic coronary heart disease caused by decrease in von Willebrand factor cleaving protease activity? A study by an immunoassay with antibody against intact bond 842Tyr-843Met of the von Willebrand factor protein
He S, Cao Hl, Magnusson Cgm, Eriksson-berg M, Mehrkash M, Schenck-gustafsson K, et al
THROMBOSIS RESEARCH 2001;103(3):241-8

A simple and rapid laboratory method for determination of haemostasis potential in plasma II. Modifications for use in routine laboratories and research work
He S, Antovic A, Blomback M
THROMBOSIS RESEARCH 2001;103(5):355-61

Evaluation of a new immunoturbidimetric test (Liatest (R) antithrombin III) for determination of antithrombin antigen
Antovic J, Soderstrom J, Karlman B, Blomback M
CLINICAL AND LABORATORY HAEMATOLOGY 2001;23(5):313-6

Hypercoagulation in surgical postmenopausal women having hormone replacement with overdose estradiol
He S, Bremme K, Silveira A, Van Rooijen M, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 2001;12(8):677-81

Measurement of activated protein C resistance during menstrual cycle in women with and without the Leiden mutation
Wramsby Ml, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 2001;85(4):614-8

Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system
He S, Blomback M, Yoo G, Sinha R, Henschen-edman Ah, Nieuwenhuizen W, et al
FIBRINOGEN 2001;:531-5

Total thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and pro-TAFI in patients with haemophilia A
Antovic J, Schulman S, Eelde A, Blomback M
HAEMOPHILIA 2001;7(6):557-60

Decrease in protein C inhibitor activity and acquired APC resistance during normal pregnancy
He S, Wramsby M, Bokarewa M, Blomback M, Bremme K
JOURNAL OF THROMBOSIS AND THROMBOLYSIS 2000;9(3):277-81

Effect of rFVIIa on the permeability of fibrin gel.
He S, Blomback M, Hedner U
BLOOD 2000;96(11):261A-261A

Haemostatic function in patients undergoing coronary artery bypass grafting: Peroperative perturbations and relations to saphenous vein graft closure
Moor E, Blomback M, Silveira A, Wiman B, Cederlund K, Bergstrand L, et al
THROMBOSIS RESEARCH 2000;98(1):39-49

Improved metabolic control increases fibrin gel porosity in patients with type 1 diabetes
Jorneskog G, Ardalani K, Karlen A, Salomonsson Ac, Blomback M
DIABETOLOGIA 2000;:A267-A267

More porous fibrin gel structure obtained by interaction with Lys-plasminogen than with Glu-plasminogen
Fatah-ardalani K, Wallen P, Petersen Lc, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 2000;11(4):335-42

Response to activated protein C during normal menstrual cycle and ovarian stimulation
Wramsby Ml, Bokarewa Mi, Blomback M, Bremme Ak
HUMAN REPRODUCTION 2000;15(4):795-7

A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results
He S, Bremme K, Blomback M
THROMBOSIS RESEARCH 1999;96(2):145-56

A laboratory method for determination of overall haemostatic potential in plasma: Method design and preliminary results
He S, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1999;:555-555

Can the laboratory assay of protein C activity assist in monitoring the hemostatic function in pre-eclampsia?
He S, Bremme K, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1999;10(3):127-32

Comparison of PLa production in women with thrombosis and repeated foetal loss
Bokarewa Mi, Wramsby M, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1999;:104-104

Decreases in protein C inhibitor activity and acquired APC resistance during normal pregnancy
He S, Wramsby M, Bokarewa M, Blomback M, Bremme K
THROMBOSIS AND HAEMOSTASIS 1999;:537-537

Does improved metabolic control positively influence fibrin gel structure in diabetic patients?
Jorneskog G, Fatah K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1999;:320-320

Evaluation of four aPTT based APC resistance measurements in women
Wramsby M, Bokarewa M, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1999;:310-310

Haemostatic, endothelial and lipoprotein parameters and blood pressure levels in women with a history of preeclampsia
He S, Silveira A, Hamsten A, Blomback M, Bremme K
THROMBOSIS AND HAEMOSTASIS 1999;81(4):538-42

Prevalence of factor V G1691A mutation and prothrombin 20210A polymorphism in women with habitual abortions
Wramsby M, Bremme K, Linder Ms, Blomback M
THROMBOSIS AND HAEMOSTASIS 1999;:541-542

Scientific visits to the Aland islands
Blomback M
HAEMOPHILIA 1999;:12-8

The progesterone/oestradiol ratio and APC-response in healthy women
Bokarewa Mi, Wramsby M, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1999;:552-553

Thrombin inhibitors suppress the thrombin-thrombomodulin-mediated generation of activated protein C
Linder R, Blomback M, Egberg N, Grip L
THROMBOSIS RESEARCH 1999;95(2):117-25

A pharmacokinetic study of dalteparin (Fragmin (R)) during late pregnancy
Blomback M, Bremme K, Hellgren M, Lindberg H
BLOOD COAGULATION & FIBRINOLYSIS 1998;9(4):343-50

Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid
Williams S, Fatah K, Hjemdahl P, Blomback M
EUROPEAN HEART JOURNAL 1998;19(11):1666-72

Coagulation factor V (Arg(506)-> Gln) mutation and early saphenous vein graft occlusion after coronary artery bypass grafting
Moor E, Silveira A, Van't Hooft F, Tornvall P, Blomback M, Wiman B, et al
THROMBOSIS AND HAEMOSTASIS 1998;80(2):220-4

Decreases in concentrations of protein C inhibitor may contribute to development of APC-resistance: A study on normal pregnancy
He S, Bremma K, Blomback M, Bokareva M, Wramsby M
BRITISH JOURNAL OF HAEMATOLOGY 1998;102(1):251-251

Effects of aprotinin during cardiopulmonary bypass in patients treated with acetylsalicylic acid
Ivert T, Intonti M, Stain-malmgren R, Dumitrescu A, Blomback M
SCANDINAVIAN CARDIOVASCULAR JOURNAL 1998;32(5):289-95

Failure to achieve gene conversion with chimeric circular oligonucleotides: Potentially misleading PCR artifacts observed
Zhang Zp, Eriksson M, Falk G, Graff C, Presnell Sc, Read Ms, et al
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT 1998;8(6):531-6

Fibrin D-dimer levels in preeclamptic pregnancies with birth of small-for-gestational-age neonates
He S, Bremme K, Blomback M
HYPERTENSION IN PREGNANCY 1998;17(2):217-226

Fibrin gel structure in diabetic patients before and during treatment with acetylsalicylic acid: a pilot study
Jorneskog G, Fatah K, Blomback M
FIBRINOLYSIS & PROTEOLYSIS 1998;12(6):360-365

Local vs. systemic immune and haemostatic response to hip arthroplasty
Kristiansson M, Soop M, Sundqvist Kg, Soop A, Suontaka Am, Blomback M
EUROPEAN JOURNAL OF ANAESTHESIOLOGY 1998;15(3):260-70

Thromboprophylaxis with low molecular mass heparin, 'Fragmin' (dalteparin), during pregnancy - a longitudinal safety study
Blomback M, Bremme K, Hellgren M, Siegbahn A, Lindberg H
BLOOD COAGULATION & FIBRINOLYSIS 1998;9(1):1-9

Acquired deficiency of antithrombin associated with a hypercoagulable state and damage of liver and kidney in preeclampsia
He S, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1997;:P1774-P1774

Acquired deficiency of antithrombin in association with a hypercoagulable state and impaired function of liver and/or kidney in preeclampsia
He S, Bremme K, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1997;8(4):232-8

Alpha fibrinogen genotype is associated with the porosity and density of the fibrin gel matrix in MI patients
Curran Jm, Fatah K, Blomback M, Humphries S, Hamsten A, Green Fr
ATHEROSCLEROSIS 1997;134(1-2):189-189

A new approach to gene therapy
Zhang Zp, Eriksson M, Blomback M, Anvret M
BLOOD COAGULATION & FIBRINOLYSIS 1997;:S39-42

Antithrombin III supplementation for patients undergoing PTCA for unstable angina pectoris - A controlled randomized double-blind pilot study
Grip L, Blomback M, Egberg N, Olsson A, Svane B, Velander M
EUROPEAN HEART JOURNAL 1997;18(3):443-9

APC resistance and its relation to thrombotic incidence during pregnancy and puerperium
Bremme K, Wramsby M, Bokarewa M, Blomback M
THROMBOSIS AND HAEMOSTASIS 1997;:P2979-P2979

Combination of activated protein C resistance and antibodies to phospholipids in the development of thrombosis
Bokarewa Mi, Blomback M
SEMINARS IN HEMATOLOGY 1997;34(3):235-43

Desmopressin in the treatment of menorrhagia
Edlund M, Blomback M
THROMBOSIS AND HAEMOSTASIS 1997;:P1813-P1813

Effect of thrombin inhibitors on activated protein C
Linder R, Blomback M, Egberg N, Grip L
THROMBOSIS AND HAEMOSTASIS 1997;:O2388-O2388

[European plasma at risk to be eleminated. The prize is too high when compared with the USA]
Blombäck M, Söderström T, Wahlberg T
Lakartidningen 1997;94(1-2):15-6

Local wound and systemic coagulation/fibrinolysis responses in hip arthroplasty - Influence of allogeneic and autologous blood transfusion
Kristiansson Me, Soop A, Keisu K, Soop M, Suontaka Am, Blomback M
ACTA ORTHOPAEDICA SCANDINAVICA 1997;68(3):221-4

Low or medium dose acetylsalicylic acid increases fibrin gel porosity is healthy adults
Fatah K, Williams S, Hjemdahl P, Blomback M
ATHEROSCLEROSIS 1997;134(1-2):190-190

Macromolecular protein complex in human plasma may explain altered fibrin gel structure in IDDM patients - Response
Jorneskog G, Fatah K, Blomback M
DIABETOLOGIA 1997;40(7):869-869

Prediction of changes in levels of haemostatic variables during natural menstrual cycle and ovarian hyperstimulation
Andersson O, Blomback M, Bremme K, Wramsby H
THROMBOSIS AND HAEMOSTASIS 1997;77(5):901-4

Production of phospholipid antibodies (PLa) by the carriers and non-carriers of the Arg506-Gln mutation in factor V
Bokarewa Mi, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1997;:P2183-P2183

Properties and units in the clinical laboratory sciences .5. Properties and units in thrombosis and haemostasis
Blomback M, Dybkaer R, Jorgensen K, Olesen H, Thorsen S
PURE AND APPLIED CHEMISTRY 1997;69(5):1043-1079

Search for mutations in the genes for coagulation factors V and VIII with a possible predisposition to activated protein C resistance
Bokarewa Mi, Falk G, Bremme K, Blomback M, Wiman B
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION 1997;27(4):340-5

The effect of progesterone on the haemostatic mechanism
Blomback M, Landgren Bm, Stiernholm Y, Andersson O
THROMBOSIS AND HAEMOSTASIS 1997;77(1):105-8

The impact of factor VIII in the fluctuation of APC response in healthy pregnant women
Bokarewa Mi, Wramsby M, Mehrkash M, Bremme K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1997;:P1303-P1303

Understanding von Willebrand's disease from gene defects to the patients
Zhang Zp, Blomback M, Anvret M
JOURNAL OF INTERNAL MEDICINE 1997;:115-9

Variability of the response to activated protein C during normal pregnancy
Bokarewa Mi, Wramsby M, Bremme K, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1997;8(4):239-44

Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient?
Fatah K, Beving H, Albage A, Ivert T, Blomback M
EUROPEAN HEART JOURNAL 1996;17(9):1362-6

Altered properties of fibrin gel structure in patients with IDDM
Jorneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, et al
DIABETOLOGIA 1996;:905-905

Altered properties of the fibrin gel structure in patients with IDDM
Jorneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, et al
DIABETOLOGIA 1996;39(12):1519-23

Arg(506)-Gln mutation in factor V and risk of thrombosis during pregnancy
Bokarewa Mi, Bremme K, Blomback M
BRITISH JOURNAL OF HAEMATOLOGY 1996;92(2):473-8

Bedside heparin monitoring by activated partial thromboplastin time measured with a dry reagent
Linder R, Grip L, Olason E, Blomback M
CLINICAL CHEMISTRY 1996;42(9):1488-9

Decrease in plasminogen activator inhibitor type 2 related more to placental function and intrauterine fetal growth than to severity of preeclampsia
He S, Bremme K, Almqvist I, Blomback M
HYPERTENSION IN PREGNANCY 1996;15(2):171-182

Hemostatic abnormalities may predict chronic hypertension after preeclampsia
Bremme K, Blomback M
GYNECOLOGIC AND OBSTETRIC INVESTIGATION 1996;41(1):20-6

On the value of menorrhagia as a predictor for coagulation disorders
Edlund M, Blomback M, Vonschoultz B, Andersson O
AMERICAN JOURNAL OF HEMATOLOGY 1996;53(4):234-8

Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age
Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A
THROMBOSIS AND HAEMOSTASIS 1996;76(4):535-40

Stability of blood coagulation factors and inhibitors in blood drawn into half-strength citrate anticoagulant
Suontaka Am, Akerblom O, Blomback M, Eriksson L, Hogman Cf, Payrat Jm
VOX SANGUINIS 1996;71(2):97-102

ACETYLSALICYLIC-ACID MAY PROTECT THE PATIENT BY INCREASING FIBRIN GEL POROSITY - DANGER OF WITHDRAWING TREATMENT
Fatah K, Beving H, Albage A, Iver T, Blomback M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1228-1228

ANTITHROMBIN(III) SUPPLEMENTATION TO PATIENTS UNDERGOING PTCA FOR UNSTABLE ANGINA-PECTORIS
Grip L, Blomback M, Egberg N, Olsson A, Svane B, Velander M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1250-1250

A PRESENT LEVEL OF HEMOSTATIC VARIABLE MAY PREDICT WHAT HAPPENS UNDER HORMONAL INFLUENCE
Blomback M, Andersson O, Bremme K, Wramsby H
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1233-1233

A TURBIDIMETRIC ASSAY FOR ASSESSING THE EFFECTS OF ACETYLSALICYLIC-ACID ON FIBRINOLYTIC POTENTIAL IN CARDIOVASCULAR-DISEASE PATIENTS
Williams S, Fatah K, Blomback M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1227-1227

CHANGES IN THE RESPONSE TO ACTIVATED PROTEIN-C DURING PREGNANCY
Bokarewa Mi, Blomback M, Bremme K
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1377-1377

COAGULATION-FACTOR-VII MASS AND ACTIVITY IN YOUNG MEN WITH MYOCARDIAL-INFARCTION AT A YOUNG AGE - ROLE OF PLASMA-LIPOPROTEINS AND FACTOR-VII GENOTYPE
Moor E, Silveira A, Vanthooft F, Suontaka Am, Eriksson P, Blomback M, et al
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 1995;15(5):655-64

Cytokine and coagulation characteristics of retrieved blood after arthroplasty
Kristiansson M, Soop M, Saraste L, Sundqvist Kg, Suontaka Am, Blomback M
INTENSIVE CARE MEDICINE 1995;21(12):989-95

EFFECTS OF THE MUTANT VON-WILLEBRAND-FACTOR GENE IN VON-WILLEBRAND DISEASE
Zhang Zp, Lindstedt M, Blomback M, Anvret M
HUMAN GENETICS 1995;96(4):388-94

EFFECTS OF THE MUTANT VON-WILLEBRAND-FACTOR GENE IN VON-WILLEBRAND DISEASE
Zhang Zp, Blomback M, Anvret M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1163-1163

FIBRINOGEN GENOTYPE, PLASMA-FIBRINOGEN LEVEL AND FIBRIN GEL PROPERTIES IN YOUNG MYOCARDIAL-INFARCTION PATIENTS AND HEALTHY CONTROLS FROM SWEDEN
Curran J, Hamsten A, Fatah K, Blomback M, Humphries S, Green F
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1379-1379

HETEROGENEITY OF APC RESISTANCE PHENOMENON AND THE MUTATION IN FACTOR-V GENE CAUSING ARG506-GLN SUBSTITUTION
Bokarewa Mi, Blomback M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1366-1366

Increased blood flow resistance in placental circulation and levels of plasminogen activator inhibitors types 1 and 2 in severe preeclampsia
He S, Bremme K, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1995;6(8):703-8

INCREASED CONCENTRATIONS OF LACTATE-DEHYDROGENASE IN PREGNANCY WITH PREECLAMPSIA - A PREDICTOR FOR THE BIRTH OF SMALL-FOR-GESTATIONAL-AGE INFANTS
He S, Bremme K, Kallner A, Blomback M
GYNECOLOGIC AND OBSTETRIC INVESTIGATION 1995;39(4):234-8

PATHOLOGICAL FIBRIN FORMATION AND COLD-INDUCED CLOTTING OF MEMBRANE OXYGENATORS DURING CARDIOPULMONARY BYPASS
Blomback M, Kronlund P, Aberg B, Fatah K, Hansson Lo, Egberg N, et al
JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA 1995;9(1):34-43

PHOSPHOLIPID ANTIBODIES AND RESISTANCE TO ACTIVATED PROTEIN-C IN WOMEN WITH THROMBOPHILIA
Bokarewa Mi, Blomback M, Bremme K
BLOOD COAGULATION & FIBRINOLYSIS 1995;6(5):417-22

PLASMINOGEN-ACTIVATOR INHIBITORS (PAI-1 AND PAI-2) IN PREECLAMPSIA - DECREASES IN PAI-2 SUGGESTING PLACENTAL OR FETAL COMPLICATIONS AND FETUS ASSUMED TO BE ONE OF REGULATORS OF PAI-2 SYNTHESIS
He S, Bremme K, Almqvist I, Blomback M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1302-1302

PROPERTIES AND UNITS IN THE CLINICAL LABORATORY SCIENCES .5. PROPERTIES AND UNITS IN THROMBOSIS AND HEMOSTASIS
Blomback M, Dybkaer R, Jorgensen K, Olesen H, Thorsen S
EUROPEAN JOURNAL OF CLINICAL CHEMISTRY AND CLINICAL BIOCHEMISTRY 1995;33(9):637-60

RELATIONSHIPS OF INSULIN AND INTACT AND SPLIT PROINSULIN TO HEMOSTATIC FUNCTION IN YOUNG MEN WITH AND WITHOUT CORONARY-ARTERY DISEASE
Bavenholm P, Proudler A, Silveira A, Crook D, Blomback M, Defaire U, et al
THROMBOSIS AND HAEMOSTASIS 1995;73(4):568-75

STUDIES ON PHOSPHOLIPID ANTIBODIES, APC-RESISTANCE AND ASSOCIATED MUTATION IN THE COAGULATION-FACTOR-V GENE
Bokarewa Mi, Bremme K, Falk G, Stenlinder M, Egberg N, Blomback M
THROMBOSIS RESEARCH 1995;78(3):193-200

The effect of acetylsalicylic acid on fibrin gel lysis by tissue plasminogen activator
Williams S, Fatah K, Ivert T, Blomback M
BLOOD COAGULATION & FIBRINOLYSIS 1995;6(8):718-25

THROMBOTIC RISK-FACTORS AND ORAL CONTRACEPTION
Bokarewa Mi, Falk G, Stenlinder M, Egberg N, Blomback M, Bremme K
JOURNAL OF LABORATORY AND CLINICAL MEDICINE 1995;126(3):294-8

THROMBOTIC RISK-FACTORS AND ORAL CONTRACEPTION (OC)
Bremme K, Blomback M, Bokarewa M, Falck G, Stenlinder M
THROMBOSIS AND HAEMOSTASIS 1995;73(6):1376-1376

Visa alla publikationer